Corrigendum to “Discovery and lead optimisation of a potent, selective and orally bioavailable RARβ agonist for the potential treatment of nerve injury” [Bioorg. Med. Chem. Lett. 29(8) (2019) 995–1000]

The authors regret that a mistake was made in the headings of Table 2, Table 3. The correct Table 2, Table 3 appear below.

Table 2.

1,2,4-Oxadiazol-3-yl benzoic acid derivatives in RAR α, β and γ transactivation assays.^a

Compd	X	β EC50 nMa	α EC50 nMa	γ EC50 nMa	Fold Selectivity for β over αb	Fold Selectivity for β over γb	cLog Pd
ATRA	–	1.9	1.2	0.9	0.6	0.5
5		1.5	18c	28	12	19	5.1
8		4200	18	17	0.0043	0.0041	7.2
9		1.4	4	3	2.8	2.1	7.2
10		1.9	26	11	13	5.6	5.3
11		2.5	19	5.3	7.6	2	5.3
12		3.4	30	6.3	9	2	5.8
13		11	114	83	10	7.5	4.1

^a–dSee Table 1.

Table 3.

Derivatives of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid in the RAR α, β and γ transactivation assays.^a

Compd	R	β EC50 nMa	α EC50 nMa	γ EC50 nMa	Fold Selectivity for β over αb	Fold Selectivity for β over γb	cLog Pd
10	H	1.9	26	11	13	5.6	5.3
14	2-F	2.2	16	8.4	7.3	3.8	5.1
15	2-Me	14	89	25	6.4	1.8	5.5
16	3-F	11	61	3.7	5.5	0.33	5.5
17	3-Me	47	600	14	13	0.3	5.5

^a,b,dSee Table 1.

The authors would like to apologise for any inconvenience caused.